Axonics, Inc. (NASDAQ:AXNX) Q1 2023 Earnings Call Transcript

You’ve got fluoroscopy there, so on and so forth. So, are there some doc’s who inject a little lidocaine and when they do the tunneling of the creating the pocket or doing the tunneling of the needle, yes, some do it that way. But I think that most people would prefer just to get some propofol, a good sleep, nice little rest. You wake up. You don’t remember much and you’re on your way. So, I understand why you’re asking this question. But I think that you, if this notion of somehow people are wanted to have things done in an office. I mean, as if that’s going to make it easier for patients or somehow more open to getting something done. I mean, I don’t know. I don’t think that the average person wants to do something in an exam room. Okay, I think you’re a lot more comfortable going through a procedure room in the hospital outpatient or an ASE.

So, I don’t think that’s a big deal. It’s not something that we’re being discussed or being requested. So I appreciate the question. But I think there’s a big difference between the fantasy or perception that something is quick and easy versus doing something that is safe and that you’re going to get great outcomes. So but I appreciate the question.

Adam Maeder: Thanks for the color Ray.

Raymond Cohen : Yes, you bet.

Operator: Thank you. One moment for our next question. And our next question comes from the line of Michael Polark from Wolfe Research. Your question please.

Michael Polark: Hey, good afternoon. I just want to be clear on the model like you didn’t mention the 2Q revenue target. Want to make sure the street is thinking about the sequential phasing correctly. So, anything that you disagree with on the street’s build prior to this update. I think 86 or so million dollars for 2Q. Is that a fair starting point?

Dan Dearen : Yes.

Raymond Cohen : Yes.

Dan Dearen : Yeah, yeah. That’s tentative.

Michael Polark: Clear. A follow up on the lead placement technology. This, how impactful is this going to be in mid ‘24 and beyond? And is this something that would kind of you’d use to enhance your operations? Or is this a product that you would look to commercialize and generate revenue from?

Raymond Cohen : So, I’m not really sure about the word operations, because this is something would be used by physicians. We’re obviously keen on this approach because what it does is it, it just makes – I mean, as we said in the headline of our news releases, it just makes things faster and easier for people to be able to find the S3 foramen. And get the needle placed than the lead placed easier without fluoroscopy. So, that’s really the key here. If you can do this procedure in the office, back to that comment, in the office without fluoroscopy without the physician or a nurse practitioner or RN or whatever, their title might be having to wear lead, it’s kind of a big deal. And also this is now allowing for a little bit of pre-case planning if you may.